Intellia Therapeutics (NTLA) Gains from Investment Securities (2015 - 2025)
Intellia Therapeutics (NTLA) reported Gains from Investment Securities of $5.2 million for Q4 2025, up 271.09% year-over-year from $1.4 million in Q4 2024, and up 560.0% quarter-over-quarter from $783901.0 in Q3 2025.
Intellia Therapeutics (NTLA) Gains from Investment Securities (2015 - 2025) Analysis & Trends
Intellia Therapeutics (NTLA) has 11 years of Gains from Investment Securities data on file, last reported at $5.2 million in Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at $5.2 million, up 271.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.9 million (down 165.75% YoY), and the FY2025 annual result was $5.2 million, up 963.21% from the prior year.
- Gains from Investment Securities advanced to $5.2 million in Q4 2025 per NTLA's latest filing, from $783901.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $66.9 million in Q4 2022 and troughed at -$3.0 million in Q4 2024.
- A 5-year average of $5.0 million and a median of $570950.5 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2021 and 2024: Gains from Investment Securities soared 1245.21% in 2021, then sank 1658.14% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $2.4 million in 2021, then jumped by 2646.95% to $66.9 million in 2022, then slumped by 100.26% to -$172000.0 in 2023, then slumped by 1658.14% to -$3.0 million in 2024, then soared by 271.09% to $5.2 million in 2025.
- Business Quant data shows NTLA's Gains from Investment Securities at $5.2 million in Q4 2025, $783901.0 in Q3 2025, and $720901.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.17 Mn |
| Dec 31, 2025 | 5.17 Mn |
| Sep 30, 2025 | 783,901.00 |
| Sep 30, 2025 | 783,901.00 |
| Jun 30, 2025 | 720,901.00 |
| Jun 30, 2025 | 720,901.00 |
| Dec 31, 2024 | -3.02 Mn |
| Dec 31, 2024 | -3.02 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | -172,000.00 |
| Dec 31, 2023 | -172,000.00 |
| Sep 30, 2023 | 181,743.00 |
| Sep 30, 2023 | 181,743.00 |
| Mar 31, 2023 | 100,000.00 |
| Mar 31, 2023 | 100,000.00 |